Breaking Update
TopGum Enters Pharmaceutical Market Through U.S. Gummy Manufacturing Deal
Israeli TopGum Industries enters the pharmaceutical market by acquiring U.S. gummy manufacturing operations for up to $37 million, including FDA-compliant.
Jerusalem, 22 January, 2026 (TPS-IL) — Israeli dietary supplement manufacturer TopGum Industries has signed a binding letter of intent to acquire U.S. operations specializing in pharmaceutical and dietary supplement gummies. The deal marks TopGum’s entry into the pharmaceutical domain and includes a U.S. facility with FDA-compliant production lines for pharmaceutical-grade gummies containing active pharmaceutical ingredients.
The acquisition combines cash and equity valued at up to $37 million, including contingent consideration.
